Codexis to Participate in Jefferies Healthcare Conference
Get Alerts CDXS Hot Sheet
Join SI Premium – FREE
REDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Healthcare Conference, being held June 7-9, 2023, in New York, New York.
Management will participate in a fireside chat on Wednesday, June 7, 2023, at 1:00 pm ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. A replay will be archived for 90 days following the event.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing, nucleic acid synthesis and genomic sequencing, and – as biotherapeutic candidates – they have the potential to treat challenging diseases. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing, greater sensitivity in genomic and diagnostic applications and potentially more efficacious therapeutics. For more information, visit www.codexis.com.
For More Information
Investor ContactCarrie McKim(336) 608-9706[email protected]
Media ContactLauren Musto(781) 572-1147[email protected]
Source: Codexis, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Umbrella Lab Announces Documentation And Traceability Update For Bromantane Reference Material
- Spinach® is the Number One Vape Brand in Canada
- Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share